Vladimir Mosailov, MD

Medical Director, Medical Affairs

Dr. Mosailov has nearly 40 years of medical experience. At PharmaNet, he plans, designs, and serves as medical monitor on Phase II–IIIb clinical studies in a broad range of indications, including cardiology, infectious diseases, dermatology, and neuroscience. Prior to PharmaNet, Dr. Mosailov served for more than 20 years in pediatrics and general practice, most recently as Chief of Staff at a pediatric inpatient unit.

Thomas J. Newman, MD

President, Late Stage Development

Dr. Newman trained in pediatrics and endocrinology and then served on the faculty at the University of Minnesota Medical School. In 1980, he joined Bristol-Myers Squibb where he worked on the development of a variety of cardiovascular, anti-infective, and diagnostic products and also served as Head of Drug Safety. Prior to joining PharmaNet, Dr. Newman was Vice President of Clinical Research at a major contract research organization.

Christine Rhoda

Senior Director, Clinical Research

Ms. Rhoda has more than 17 years of experience in drug development settings, including pharmaceutical, biotechnology, and contract research organizations. Her expertise spans a range of services in clinical research, project management and medical writing. Ms. Rhoda‘s experience in pediatric research includes serving as project director for an international enzyme replacement therapy program for boys.

Philippa Smit-Marshall, MD

Vice President, Medical Affairs, Europe and Asia Pacific

Dr. Smit-Marshall trained in pharmacology and internal medicine in the UK before joining the pharmaceutical industry nearly 20 years ago. During that time she has worked for both industry and CROs and she has been involved in the development of drugs in children across several indications including epilepsy; growth disorders associated with renal failure; intrauterine growth retardation and Turner Syndrome; cystic fibrosis, and schizophrenia. Philippa chairs the institute of Clinical Research’s Special Focus group on Pediatrics.

Margarete Traiser, PhD

Director, Clinical Research

Dr. Traiser manages PharmaNet’s clinical research team in Germany as well as mentoring clinical research managers in conducting clinical trials in children of all age groups, including pre-term neonates. Before joining PharmaNet, she worked for more than 9 years in many aspects of clinical R&D within the pharmaceutical industry, including paediatric drug development. Dr. Traiser has held positions including clinical research associate, global clinical trial manager, and interdisciplinary R&D project manager for an international drug development program for an orphan disease in oncology. She studied biology, pharmacology, and toxicology in Germany and holds a PhD in Natural Science.

Jan Willem van der Velden, MD, FFPM, FISPE

Senior Vice President, Global Safety and Pharmacovigilance

Dr. van der Velden has more than 24 years of experience, including 7 years in oncology trials at the Rotterdam Radiotherapeutic Institute, where he was in charge of cancer epidemiology and the coordination and assessment of experimental treatment research. He also served 16 years in global safety at Solvay and Yamanouchi Europe. At PharmaNet, he is in charge of drug safety, pharmacovigilance, risk-and-crisis management, and pharmacoepidemiology of pharmaceuticals and devices.